Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases

Howard Eliot Gendelman, Vellareddy Anantharam, Tatiana K Bronich, Shivani Ghaisas, Huajun Jin, Anumantha G. Kanthasamy, Xinming Liu, JoEllyn M McMillan, R Lee Mosley, Balaji Narasimhan, Surya K. Mallapragada

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

Interest in nanoneuromedicine has grown rapidly due to the immediate need for improved biomarkers and therapies for psychiatric, developmental, traumatic, inflammatory, infectious and degenerative nervous system disorders. These, in whole or in part, are a significant societal burden due to growth in numbers of affected people and in disease severity. Lost productivity of the patient and his or her caregiver, and the emotional and financial burden cannot be overstated. The need for improved health care, treatment and diagnostics is immediate. A means to such an end is nanotechnology. Indeed, recent developments of health-care enabling nanotechnologies and nanomedicines range from biomarker discovery including neuroimaging to therapeutic applications for degenerative, inflammatory and infectious disorders of the nervous system. This review focuses on the current and future potential of the field to positively affect clinical outcomes.

Original languageEnglish (US)
Pages (from-to)751-767
Number of pages17
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume11
Issue number3
DOIs
StatePublished - Jan 1 2015

Fingerprint

Neurology
Biomarkers
Nervous System Diseases
Health care
Nanotechnology
Neuroimaging
Medical nanotechnology
Nanomedicine
Delivery of Health Care
Productivity
Caregivers
Psychiatry
Therapeutics
Growth

Keywords

  • Diagnostics
  • Drug development
  • Nanoneuromedicine
  • Nanotechnology
  • Neurodegenerative disorders

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this

Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. / Gendelman, Howard Eliot; Anantharam, Vellareddy; Bronich, Tatiana K; Ghaisas, Shivani; Jin, Huajun; Kanthasamy, Anumantha G.; Liu, Xinming; McMillan, JoEllyn M; Mosley, R Lee; Narasimhan, Balaji; Mallapragada, Surya K.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 11, No. 3, 01.01.2015, p. 751-767.

Research output: Contribution to journalReview article

Gendelman, Howard Eliot ; Anantharam, Vellareddy ; Bronich, Tatiana K ; Ghaisas, Shivani ; Jin, Huajun ; Kanthasamy, Anumantha G. ; Liu, Xinming ; McMillan, JoEllyn M ; Mosley, R Lee ; Narasimhan, Balaji ; Mallapragada, Surya K. / Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2015 ; Vol. 11, No. 3. pp. 751-767.
@article{02340a9542df47fba16116c619aa32a1,
title = "Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases",
abstract = "Interest in nanoneuromedicine has grown rapidly due to the immediate need for improved biomarkers and therapies for psychiatric, developmental, traumatic, inflammatory, infectious and degenerative nervous system disorders. These, in whole or in part, are a significant societal burden due to growth in numbers of affected people and in disease severity. Lost productivity of the patient and his or her caregiver, and the emotional and financial burden cannot be overstated. The need for improved health care, treatment and diagnostics is immediate. A means to such an end is nanotechnology. Indeed, recent developments of health-care enabling nanotechnologies and nanomedicines range from biomarker discovery including neuroimaging to therapeutic applications for degenerative, inflammatory and infectious disorders of the nervous system. This review focuses on the current and future potential of the field to positively affect clinical outcomes.",
keywords = "Diagnostics, Drug development, Nanoneuromedicine, Nanotechnology, Neurodegenerative disorders",
author = "Gendelman, {Howard Eliot} and Vellareddy Anantharam and Bronich, {Tatiana K} and Shivani Ghaisas and Huajun Jin and Kanthasamy, {Anumantha G.} and Xinming Liu and McMillan, {JoEllyn M} and Mosley, {R Lee} and Balaji Narasimhan and Mallapragada, {Surya K.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.nano.2014.12.014",
language = "English (US)",
volume = "11",
pages = "751--767",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases

AU - Gendelman, Howard Eliot

AU - Anantharam, Vellareddy

AU - Bronich, Tatiana K

AU - Ghaisas, Shivani

AU - Jin, Huajun

AU - Kanthasamy, Anumantha G.

AU - Liu, Xinming

AU - McMillan, JoEllyn M

AU - Mosley, R Lee

AU - Narasimhan, Balaji

AU - Mallapragada, Surya K.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Interest in nanoneuromedicine has grown rapidly due to the immediate need for improved biomarkers and therapies for psychiatric, developmental, traumatic, inflammatory, infectious and degenerative nervous system disorders. These, in whole or in part, are a significant societal burden due to growth in numbers of affected people and in disease severity. Lost productivity of the patient and his or her caregiver, and the emotional and financial burden cannot be overstated. The need for improved health care, treatment and diagnostics is immediate. A means to such an end is nanotechnology. Indeed, recent developments of health-care enabling nanotechnologies and nanomedicines range from biomarker discovery including neuroimaging to therapeutic applications for degenerative, inflammatory and infectious disorders of the nervous system. This review focuses on the current and future potential of the field to positively affect clinical outcomes.

AB - Interest in nanoneuromedicine has grown rapidly due to the immediate need for improved biomarkers and therapies for psychiatric, developmental, traumatic, inflammatory, infectious and degenerative nervous system disorders. These, in whole or in part, are a significant societal burden due to growth in numbers of affected people and in disease severity. Lost productivity of the patient and his or her caregiver, and the emotional and financial burden cannot be overstated. The need for improved health care, treatment and diagnostics is immediate. A means to such an end is nanotechnology. Indeed, recent developments of health-care enabling nanotechnologies and nanomedicines range from biomarker discovery including neuroimaging to therapeutic applications for degenerative, inflammatory and infectious disorders of the nervous system. This review focuses on the current and future potential of the field to positively affect clinical outcomes.

KW - Diagnostics

KW - Drug development

KW - Nanoneuromedicine

KW - Nanotechnology

KW - Neurodegenerative disorders

UR - http://www.scopus.com/inward/record.url?scp=84933497981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933497981&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2014.12.014

DO - 10.1016/j.nano.2014.12.014

M3 - Review article

VL - 11

SP - 751

EP - 767

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 3

ER -